183 related articles for article (PubMed ID: 36828767)
1. Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment.
Sakai R; Sekimoto T; Koba S; Mori H; Matsukawa N; Arai T; Yokota Y; Sato S; Tanaka H; Masaki R; Oishi Y; Ogura K; Arai K; Nomura K; Sakai K; Tsujita H; Kondo S; Tsukamoto S; Suzuki H; Shinke T
J Clin Lipidol; 2023; 17(2):281-290. PubMed ID: 36828767
[TBL] [Abstract][Full Text] [Related]
2. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
Ballantyne CM; Raichlen JS; Cain VA
J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline plaque characteristic on the development of neoatherosclerosis in the very late phase after stenting.
Hoshino M; Yonetsu T; Kanaji Y; Usui E; Yamaguchi M; Hada M; Hamaya R; Kanno Y; Murai T; Lee T; Kakuta T
J Cardiol; 2019 Jul; 74(1):67-73. PubMed ID: 30733110
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
5. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
6. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
[TBL] [Abstract][Full Text] [Related]
7. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
[TBL] [Abstract][Full Text] [Related]
8. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.
Ito T; Fujita H; Tani T; Ohte N
Atherosclerosis; 2015 Apr; 239(2):311-7. PubMed ID: 25682029
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Predictors of Neoatherosclerosis in Patients with Early In-Stent Restenosis Determined Using Optical Coherence Tomography.
Meng L; Liu X; Yu H; Wei G; Gu X; Chang X; Xie M; Qu W; Peng X; Sun Y; Tian J; Yu B
Int Heart J; 2020 Sep; 61(5):872-878. PubMed ID: 32921669
[TBL] [Abstract][Full Text] [Related]
10. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
11. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
12. Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults.
Haslam DE; Chasman DI; Peloso GM; Herman MA; Dupuis J; Lichtenstein AH; Smith CE; Ridker PM; Jacques PF; Mora S; McKeown NM
J Nutr; 2022 Nov; 152(11):2534-2545. PubMed ID: 36774119
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
14. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
[TBL] [Abstract][Full Text] [Related]
15. Clinical Importance of the LDL-C/Apolipoprotein B Ratio for Neointimal Formation after Everolimus-Eluting Stent Implantations.
Akutsu N; Hori K; Mizobuchi S; Ogaku A; Koyama Y; Fujito H; Arai R; Ebuchi Y; Migita S; Morikawa T; Tamaki T; Kojima K; Murata N; Nishida T; Kitano D; Fukamachi D; Okumura Y
J Atheroscler Thromb; 2022 Apr; 29(4):536-550. PubMed ID: 33746158
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
17. Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction.
Arai T; Sekimoto T; Koba S; Mori H; Matsukawa N; Sakai R; Yokota Y; Sato S; Tanaka H; Masaki R; Oishi Y; Ogura K; Arai K; Nomura K; Sakai K; Tsujita H; Kondo S; Tsukamoto S; Suzuki H; Shinke T
J Clin Lipidol; 2022; 16(5):725-732. PubMed ID: 36038471
[TBL] [Abstract][Full Text] [Related]
18. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
19. Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis.
Jang JY; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Atherosclerosis; 2015 Oct; 242(2):553-9. PubMed ID: 26318104
[TBL] [Abstract][Full Text] [Related]
20. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
